CyFlow GCPII PE (RUO)
| 品番 | BR339703 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu GCPII PE,GCP-05 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 0.1 mg/ml | ||
| 推奨使用量 | - | ||
| 容量 | 1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 PE (BV655324) |
||
| 反応性|交差吸着 | Human | レーザー | Blue, Green, Yellow |
| 抗原 | GCPII, PSMA | 最大蛍光波長 | 576 nm |
| クローン | GCP-05 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE |
| アイソタイプ | IgG1 | 研究分野 | Neurobiology |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Hu GCPII PE,GCP-05
特異性
The mouse monoclonal antibody GCP-05 recognizes extracellular domain (preferentially in native form) of GCPII (PSMA), a 95-110 kDa transmembrane glycoprotein expressed mainly in tumor neovasculatures, nervous system and jejunum, which is an important prostate tumour marker.
抗原情報
Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-α-linked acidic dipeptidase I (NAALADase I), folate hydrolase (FOLH1) and prostate-specific membrane antigen (PSMA), is an approximately 95-110 kDa type II transmembrane glycoprotein expressed in various tissues. In nervous system GCPII cleaves abundant N-acetylaspartylglutamate, which is released from neurons in a calcium-dependent manner, to N-acetylaspartate and glutamate. As immoderate glutamate concentration is neurotoxic, GCPII contributes to pathological conditions regarding e.g. Alzheimer´s disease, Huntington´s disease, epilepsy, schizophrenia, stroke or neuropathic pain and appears to be an interesting therapeutic target. In jejunum GCPII hydrolyzes pteroylpoly-γ-glutamate to folate and glutamate, enabling folate to be absorbed by gastrointestinal tract. GCPII, which is present in a number of tissues at low levels, is overexpressed in neovasculature of most solid tumors and is a target enzyme for diagnosis and treatment of prostate cancer. Normal human prostate express more mRNA coding for a cytosolic GCPII form truncated at the N-terminus (PSM´) than mRNA for membrane-bound GCPII, and this ratio is reversed upon malignant transformation.
利用方法
The reagent is designed for Flow Cytometry analysis. Suggested working usage is 0.5 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Barinka C, Mlcochova P, Sacha P, Hilgert I, Majer P, Slusher BS, Horejsi V, Konvalinka J: Amino acids at the N‑ and C‑termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. Eur·J·Biochem. 2004; 271:2782‑2790. <·PMID:·15206943·>
• Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J: Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J·Neurochem. 2002; 80:477‑487. <·PMID:·11905994·>
• Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS, Konvalinka J: Identification of the N‑glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein·Sci. 2004; 13:1627‑1635. <·PMID:·15152093·>
• Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ: Crystal structure of prostate‑specific membrane antigen, a tumor marker and peptidase. Proc·Natl·Acad·Sci·USA. 2005; 102:5981‑5986. <·PMID:·15837926·>
• Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ, Monti AL, Roos RP: Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc·Natl·Acad·Sci·USA. 2003·Aug·5; 100(16):9554‑9. <·PMID:·12876198·>
• Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R: Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO·J. 2006; 1375‑1384. <·PMID:·16467855·>
• Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J: Expression of glutamate carboxypeptidase II in human brain. Neuroscience. 2007; 144:1361‑1372. <·PMID:·17150306·>
• Tykvart J, Navrátil V, Sedlák F, Corey E, Colombatti M, Fracasso G, Koukolík F, Bařinka C, Sácha P, Konvalinka J: Comparative analysis of monoclonal antibodies against prostate‑specific membrane antigen (PSMA). Prostate. 2014·Sep·27; <·PMID:·26629066·>